(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 40.84% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.82%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Iovance Biotherapeutics's revenue in 2026 is $263,502,000.On average, 13 Wall Street analysts forecast IOVA's revenue for 2026 to be $164,508,628,523, with the lowest IOVA revenue forecast at $141,302,831,201, and the highest IOVA revenue forecast at $186,000,665,561. On average, 12 Wall Street analysts forecast IOVA's revenue for 2027 to be $226,274,032,261, with the lowest IOVA revenue forecast at $177,637,844,938, and the highest IOVA revenue forecast at $301,889,585,226.
In 2028, IOVA is forecast to generate $307,010,268,001 in revenue, with the lowest revenue forecast at $226,084,529,922 and the highest revenue forecast at $456,453,460,556.